Published in J Infect Dis on April 09, 2013
HIV treatment, preexposure prophylaxis, and drug resistance: reconciling conflicting predictions from mathematical models. J Infect Dis (2013) 1.15
Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challenges. AIDS Patient Care STDS (2014) 1.02
HIV-1 prevention with ART and PrEP: mathematical modeling insights into resistance, effectiveness, and public health impact. J Infect Dis (2013) 1.00
Exposure to MIV-150 from a high-dose intravaginal ring results in limited emergence of drug resistance mutations in SHIV-RT infected rhesus macaques. PLoS One (2014) 0.92
Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models. EBioMedicine (2015) 0.92
Healthcare Access and PrEP Continuation in San Francisco and Miami Following the U.S. PrEP Demo Project. J Acquir Immune Defic Syndr (2016) 0.89
Global epidemiology of HIV. Infect Dis Clin North Am (2014) 0.87
How could preventive therapy affect the prevalence of drug resistance? Causes and consequences. Philos Trans R Soc Lond B Biol Sci (2015) 0.86
Combination HIV prevention among MSM in South Africa: results from agent-based modeling. PLoS One (2014) 0.86
Antiretroviral treatment, preexposure prophylaxis, and drug resistance in sub-Saharan Africa: a consensus among mathematical models. J Infect Dis (2013) 0.86
Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis? Curr Opin HIV AIDS (2016) 0.84
Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq. Retrovirology (2014) 0.82
Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to prevention. Retrovirology (2013) 0.79
Characteristics Associated with HIV Drug Resistance Among Women Screening for an HIV Prevention Trial in KwaZulu-Natal, South Africa. AIDS Behav (2015) 0.78
Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa. Clin Infect Dis (2016) 0.77
Potential impact of multiple interventions on HIV incidence in a hyperendemic region in Western Kenya: a modelling study. BMC Infect Dis (2016) 0.77
Estimation and Short-Term Prediction of the Course of the HIV Epidemic Using Demographic and Health Survey Methodology-Like Data. PLoS One (2015) 0.76
Deciphering the Effects of Injectable Pre-exposure Prophylaxis for Combination Human Immunodeficiency Virus Prevention. Open Forum Infect Dis (2016) 0.75
Impact of Population Recruitment on the HIV Epidemics and the Effectiveness of HIV Prevention Interventions. Bull Math Biol (2016) 0.75
HIV treatment as prevention: contradictory perspectives from dynamic mathematical models. ScientificWorldJournal (2014) 0.75
A curative regimen would decrease HIV prevalence but not HIV incidence unless targeted to an ART-naïve population. Sci Rep (2016) 0.75
[Factors associated with non-adherence of adults infected with HIV on antiretroviral therapy in a referral hospital in Douala]. Pan Afr Med J (2015) 0.75
How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact. PLoS One (2016) 0.75
Antimicrobial Resistance Risks of Cholera Prophylaxis for United Nations Peacekeepers. Antimicrob Agents Chemother (2017) 0.75
Combined interventions to reduce HIV incidence in KwaZulu-Natal: a modelling study. BMC Infect Dis (2017) 0.75
Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. J Virus Erad (2017) 0.75
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet (2008) 36.01
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis (2005) 21.08
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med (2012) 20.03
Preexposure prophylaxis for HIV infection among African women. N Engl J Med (2012) 15.28
Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med (2011) 11.05
Vital signs: HIV prevention through care and treatment--United States. MMWR Morb Mortal Wkly Rep (2011) 6.90
HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis (2011) 5.94
Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med (2001) 5.33
Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis (2010) 4.41
Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Med (2007) 3.56
A decline in new HIV infections in South Africa: estimating HIV incidence from three national HIV surveys in 2002, 2005 and 2008. PLoS One (2010) 3.38
Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis (2009) 3.37
Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis (2011) 3.16
Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. AIDS (2008) 2.91
Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS One (2007) 2.84
Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J Virol (2008) 2.56
Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies. Sex Transm Infect (2008) 2.49
Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa. AIDS (2011) 2.38
Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS (2010) 2.33
Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis (2012) 2.26
Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa. J Acquir Immune Defic Syndr (2011) 2.16
Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol (2001) 2.08
The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. AIDS (2010) 1.92
Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis (2011) 1.90
The failure of routine rapid HIV testing: a case study of improving low sensitivity in the field. BMC Health Serv Res (2010) 1.61
Outcomes of antiretroviral treatment programs in rural Southern Africa. J Acquir Immune Defic Syndr (2012) 1.60
Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy. Sex Transm Infect (2010) 1.59
Determining transition probabilities: confusion and suggestions. Med Decis Making (1994) 1.35
Evolutionary pathways of transmitted drug-resistant HIV-1. J Antimicrob Chemother (2011) 1.28
The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. AIDS (2010) 1.01
Transmission dynamics of the M184V drug resistance mutation in primary HIV infection. J Antimicrob Chemother (2011) 0.91
Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med (2002) 9.70
Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med (2008) 8.50
New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (2003) 8.25
Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol (2005) 7.91
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A (2008) 6.70
Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity (2008) 5.86
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis (2008) 5.20
ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog (2007) 4.82
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis (2003) 4.51
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med (2010) 3.24
Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med (2010) 3.14
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA (2002) 2.96
Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS (2009) 2.91
Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS One (2007) 2.84
Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS (2006) 2.71
Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr (2002) 2.70
Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 Cell count slope for progression to AIDS and death in untreated HIV-1 infection. JAMA (2007) 2.59
Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr (2010) 2.46
Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol (2006) 2.45
Accuracy of the TRUGENE HIV-1 genotyping kit. J Clin Microbiol (2003) 2.32
Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients. J Infect Dis (2010) 2.15
Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. Proc Natl Acad Sci U S A (2011) 1.93
Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase. AIDS (2008) 1.91
In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase. Antimicrob Agents Chemother (2005) 1.83
Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc Natl Acad Sci U S A (2005) 1.79
Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa. AIDS Res Treat (2010) 1.75
The need for treatment interruption studies and biomarker identification in the search for an HIV cure. AIDS (2015) 1.68
Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings. J Acquir Immune Defic Syndr (2006) 1.62
The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir/ritonavir alone. AIDS (2006) 1.60
The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol (2006) 1.59
Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine. J Virol (2007) 1.57
HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol (2010) 1.57
Genetic correlates of efavirenz hypersusceptibility. AIDS (2004) 1.50
Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase. AIDS (2007) 1.47
Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells. J Biol Chem (2011) 1.45
Analysis of 454 sequencing error rate, error sources, and artifact recombination for detection of Low-frequency drug resistance mutations in HIV-1 DNA. Retrovirology (2013) 1.45
Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proc Natl Acad Sci U S A (2011) 1.42
Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models. AIDS (2013) 1.42
No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr (2012) 1.39
Viremic relapse after HIV-1 remission in a perinatally infected child. N Engl J Med (2015) 1.37
Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother (2006) 1.37
Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities. J Int AIDS Soc (2010) 1.35
Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIV-related lymphoma. J Acquir Immune Defic Syndr (2013) 1.34
The 3'-azido group is not the primary determinant of 3'-azido-3'-deoxythymidine (AZT) responsible for the excision phenotype of AZT-resistant HIV-1. J Biol Chem (2005) 1.30
Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy. J Virol (2007) 1.30
Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level. J Infect Dis (2006) 1.29
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. J Infect Dis (2009) 1.28
Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP). PLoS One (2011) 1.26
Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. J Infect Dis (2013) 1.26
Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (2002) 1.25
The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS (2016) 1.25
Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog. AIDS (2013) 1.24
YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor. Am J Pathol (2008) 1.23
Genetic diversity of simian immunodeficiency virus encoding HIV-1 reverse transcriptase persists in macaques despite antiretroviral therapy. J Virol (2010) 1.21
Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy. Clin Infect Dis (2011) 1.18
HIV populations are large and accumulate high genetic diversity in a nonlinear fashion. J Virol (2013) 1.17
A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis (2012) 1.17
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA (2006) 1.14
Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. Clin Infect Dis (2012) 1.11
Multiple sources of contamination in samples from patients reported to have XMRV infection. PLoS One (2012) 1.08
Optimization of allele-specific PCR using patient-specific HIV consensus sequences for primer design. J Virol Methods (2009) 1.08
New tools for quantifying HIV-1 reservoirs: plasma RNA single copy assays and beyond. Curr HIV/AIDS Rep (2012) 1.08
Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 Reverse transcriptase facilitates dual resistance to zidovudine and lamivudine. Antimicrob Agents Chemother (2007) 1.07
A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS (2010) 1.05
Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors. AIDS (2006) 1.04
Sensitive phenotypic detection of minor drug-resistant human immunodeficiency virus type 1 reverse transcriptase variants. J Clin Microbiol (2005) 1.03
Mechanism by which a glutamine to leucine substitution at residue 509 in the ribonuclease H domain of HIV-1 reverse transcriptase confers zidovudine resistance. Biochemistry (2008) 1.02
Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS (2003) 1.02
Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. AIDS (2005) 1.01
In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine. Antimicrob Agents Chemother (2005) 0.99
Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users. AIDS (2004) 0.99
Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009). PLoS One (2013) 0.99
Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women. Antivir Ther (2011) 0.97
Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV. Clin Infect Dis (2013) 0.96
Simplification strategies to reduce antiretroviral drug exposure: progress and prospects. Antivir Ther (2009) 0.96
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Top HIV Med (2009) 0.93
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides. Antimicrob Agents Chemother (2009) 0.91
Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy. Antivir Ther (2012) 0.90
Nonhuman primate models for HIV cure research. PLoS Pathog (2012) 0.90
A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir. Antivir Ther (2003) 0.90
Comparing vector–host and SIR models for dengue transmission. Math Biosci (2013) 0.90
A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen. HIV Clin Trials (2011) 0.89
A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086. J Infect Dis (2006) 0.88
Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy. Antivir Ther (2011) 0.88
Y chromosome and HIV DNA detection in vaginal swabs as biomarkers of semen and HIV exposure in women. Sex Transm Dis (2014) 0.88
Recovery of replication-competent HIV type 1-infected circulating monocytes from individuals receiving antiretroviral therapy. AIDS Res Hum Retroviruses (2002) 0.86
Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward. Proc Natl Acad Sci U S A (2002) 0.86
Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV. HIV Clin Trials (2008) 0.86
Antiretroviral treatment, preexposure prophylaxis, and drug resistance in sub-Saharan Africa: a consensus among mathematical models. J Infect Dis (2013) 0.86
Amplifying and quantifying HIV-1 RNA in HIV infected individuals with viral loads below the limit of detection by standard clinical assays. J Vis Exp (2011) 0.86
Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP. J Infect Dis (2014) 0.86
Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis? Curr Opin HIV AIDS (2016) 0.84